MIST — Milestone Pharmaceuticals Share Price
0.000.00%
Last trade - 00:00- $87.17m
- $70.93m
- $1.00m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 5.2 | ||
| Price to Tang. Book | 5.2 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 87.17 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -89.85% | ||
| Return on Equity | -143.61% | ||
| Operating Margin | -6109.8% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | 15 | 5 | 1 | n/a | 13.5 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Milestone Pharmaceuticals Inc. is a Canada-based biopharmaceutical company. The Company is focused on the development and commercialization of cardiovascular medicines. Its lead product candidate, etripamil, is a potent rapid-onset calcium channel blocker that the Company designed and is developing as a rapid-onset nasal spray to be administered by patients. The Company is also focused on developing etripamil to treat paroxysmal supraventricular tachycardia (PSVT) with a subsequent indication to treat atrial fibrillation with rapid ventricular rate (AFib-RVR) and other cardiovascular indications.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- July 16th, 2003
- Public Since
- May 9th, 2019
- No. of Shareholders
- 19
- No. of Employees
- 47
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 53,149,778
- Address
- 420-1111 boul. Dr.-Frederik-Philips, MONTREAL, H4M 2X6
- Web
- https://www.milestonepharma.com
- Phone
- +1 5143360444
- Contact
- David Pitts
- Auditors
- PricewaterhouseCoopers LLP
Upcoming Events for MIST
Milestone Pharmaceuticals Inc Annual Shareholders Meeting
Milestone Pharmaceuticals Inc Annual Shareholders Meeting
Q2 2024 Milestone Pharmaceuticals Inc Earnings Release
Similar to MIST
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
What is the Milestone Pharmaceuticals share price?
As of Today at 19:14 UTC, shares in Milestone Pharmaceuticals are trading at $1.64. This share price information is delayed by 15 minutes.
How has the Milestone Pharmaceuticals share price performed this year?
Shares in Milestone Pharmaceuticals last closed at $1.64 and the price had moved by -58.27% over the past 365 days. In terms of relative price strength the Milestone Pharmaceuticals share price has underperformed the S&P500 Index by -65.27% over the past year.
What are the analyst and broker recommendations for Milestone Pharmaceuticals?
The overall consensus recommendation for Milestone Pharmaceuticals is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Milestone Pharmaceuticals dividend yield?
Milestone Pharmaceuticals does not currently pay a dividend.
Does Milestone Pharmaceuticals pay a dividend?
Milestone Pharmaceuticals does not currently pay a dividend.
When does Milestone Pharmaceuticals next pay dividends?
Milestone Pharmaceuticals does not currently pay a dividend.
How do I buy Milestone Pharmaceuticals shares?
To buy shares in Milestone Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Milestone Pharmaceuticals?
As of the previous close price of $1.64, shares in Milestone Pharmaceuticals had a market capitalisation of $87.17m.
Where are Milestone Pharmaceuticals shares listed?
Here are the trading details for Milestone Pharmaceuticals:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: MIST
What kind of share is Milestone Pharmaceuticals?
Based on an overall assessment of its quality, value and momentum Milestone Pharmaceuticals is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Milestone Pharmaceuticals share price forecast for 2024?
The analyst consensus target price for shares in Milestone Pharmaceuticals is $10.50. That is 540.24% above the last closing price of $1.64.
Analysts covering Milestone Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of -$1.15 for the next financial year.
What is the trend in the Milestone Pharmaceuticals share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Milestone Pharmaceuticals. Over the past six months, its share price has underperformed the S&P500 Index by -48.62%.
As of the last closing price of $1.64, shares in Milestone Pharmaceuticals were trading -32.41% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Milestone Pharmaceuticals PE Ratio?
The Milestone Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.64.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Milestone Pharmaceuticals?
We do not have data on Milestone Pharmaceuticals' directors